Clinical trial NCT01731925: A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Official title: A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Carcinoid Tumors
Keywords: midgut carcinoid tumors
progressive
advanced
metastatic
Lead sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Sponsor class: OTHER
Collaborators: name: Pfizer
name: Ipsen
First posted: 2012-11-22
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Sunitinib may provide an opportunity for a novel therapeutic strategy for the treatment of subjects with neuroendocrine tumors.

Detailed description: With the exception of surgery for localized disease, there is presently a lack of available therapies with proven survival benefit for patients with neuroendocrine tumors (NET). Available treatment options for unresectable disease include the use of somatostatin analogs, which may relieve symptoms related to hormonal hypersecretion. The efficacy of cytotoxic chemotherapy in patients with metastatic carcinoid tumors is also limited. Combinations of either streptozocin and cyclophosphamide, or streptozocin and 5-fluorouracil, appear to be inactive, and both regimens are associated with substantial toxicity.

Receptor tyrosine kinases (RTKs) are implicated in deregulated/ autocrine proliferation and survival of solid and hematologic cancer cells. Sunitinib malate is an orally administered small molecule that inhibits the tyrosine kinase enzymatic activities of the receptors for VEGF and PDGF, and also blocks signalling through the KIT, FLT3 and RET pathways.

Therefore, sunitinib malate may provide an opportunity for a novel therapeutic strategy for the treatment of subjects with NET.

Eligibility criteria: Inclusion Criteria:

1. Patients with midgut well-differentiated Grade 1-2 endocrine tumor.
2. Local, locally advanced or metastatic disease documented as progressive by RECIST v1.1. on CT-scan or MRI at baseline and within 12 months prior to baseline.
3. 5HIAA levels superior to 1.5ULN as measured in each individual centre.
4. Disease that is not amenable to surgery with curative intent.
5. Presence of at least one measurable target lesion for further evaluation according to RECIST v1.1
6. Adequate organ function
7. ECOG Performance status 0 or 1.
8. Life expectancy superior or equal to 3 months.
9. Age superior or equal to 18 years.
10. Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment. Breast feeding is not allowed. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
11. Able to swallow oral compound.
12. Signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial prior to enrollment.
13. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures.
14. Registration in a national health care system (CMU included).

Exclusion Criteria:

1. Patients with undifferentiated, poorly differentiated gastrointestinal neuroendocrine tumors, pancreatic neuroendocrine tumors, bronchial carcinoid tumors.
2. Patients with carcinoid tumors with the presence of an obstructive intestinal tumor.
3. Patients with uncontrolled cardiac complication as part of their carcinoid syndrome.
4. Current treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or investigational anticancer agent
5. Current treatment with dose superior or equal to 120 mg per month of lanreotide
6. Prior treatment with any tyrosine kinase inhibitors or anti-VEGF angiogenic inhibitors. Prior treatment with non-VEGF-targeted angiogenic inhibitors such as everolimus or temsirolimus is permitted.
7. Patients who stopped everolimus treatment was less than 4 weeks prior to randomization.
8. Patients with concomitant treatment with interferon.
9. Patients previously treated with chemotherapy, loco-regional therapy (e.g., chemoembolization) or interferon with last administration less than 6 weeks prior to randomization or with toxicity not resolved to less or equal grade 1 at randomization.
10. Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri.
11. Treatment with potent CYP3A4 inhibitors and inducers within 7 and 12 days, respectively prior to study drug administration.
12. Concomitant treatment with therapeutic doses of anticoagulants
13. Concomitant treatment with a drug having proarrhythmic potential
14. Unstable systemic diseases including uncontrolled hypertension or active uncontrolled infections.
15. Current treatment on another clinical trial.
16. Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
17. Ongoing cardiac dysrhythmias of NCI CTC grade superior or equal to 2, atrial fibrillation of any grade, or prolongation of the QTc interval to more than 450 msec for males or more than 470 msec for females.
18. Symptomatic brain metastases, spinal cord compression, or new evidence of brain or leptomeningeal disease.
19. Left ventricular ejection fraction inferior or equal 50% as measured by either multigated acquisition scan or echocardiogram.
20. Positive test for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
21. Patients with complicated, untreated lithiasis of the bile ducts
22. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.

Primary outcomes:
measure: Progression free survival (PFS)
timeFrame: time from date of randomization to first progression of disease (PD) or death for any reason in the absence of documented PD, assessed up to 3 years after the beginning of the study
Secondary outcomes:
measure: Overall survival (OS)
timeFrame: time from date of randomization to date of death, assessed up to 3 years after the beginning of the study
measure: Objective response (OR)
timeFrame: from randomization until disease progression, assessed up to 3 years after the beginning of the study
measure: Duration of response (DR)
timeFrame: time from CR or PR to objective tumor progression or to death due to any cause, whichever occurs first, assessed up to 3 years after the beginning of the study
measure: Time to tumor response (TTR)
timeFrame: time from date of randomization to first documentation of objective tumor response that is subsequently confirmed.assessed up to 3 years after the beginning of the study
measure: Biological responses
timeFrame: from baseline to end of treatment, assessed up to 3 years after the beginning of the study
measure: Safety
timeFrame: from visit 1 to 1 month after last study drug administration, assessed up to 3 years after the beginning of the study
measure: Quality of life
timeFrame: From screening to 1 month after last study drug administration, assessed up to 3 years after the beginning of the study
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Cliniques Universitaires Saint Luc
city: Brussels
country: Belgium
facility: Institut Jules Bordet
city: Brussels
country: Belgium
facility: ULB Erasme
city: Edegem
country: Belgium
facility: UZ Antwerpen
city: Gent
country: Belgium
facility: UZ Gent
city: Leuven
country: Belgium
facility: UZ Leuven
city: Bordeaux
country: France
facility: Hôpital Saint André
city: Clichy
country: France
facility: Hôpital Beaujon
city: Créteil
country: France
facility: Hôpital Henri Mondor
city: Lille
country: France
facility: Hopital Saint Vincent de Paul
city: Lyon
country: France
facility: Hôpital Edouard Herriot
city: Marseille
country: France
facility: CHU La Timone
city: Paris
country: France
facility: Hôpital St Antoine
city: Paris
country: France
facility: CHU Cochin
city: Paris
country: France
facility: Hôpital Pitié Salpêtrière
city: Paris
country: France
facility: Institut Mutualiste Montsouris
city: Reims
country: France
facility: CHU Robert Debré
city: Rennes
country: France
facility: CHU Pontchaillou
city: Rouen
country: France
facility: CHU Rouen
city: Tours
country: France
facility: CHRU Trousseau
Study officials:
affiliation: Hôpital Beaujon
name: Pascal HAMMEL, MD
role: PRINCIPAL_INVESTIGATOR
References: